GVS advice CGRP inhibitors erenumab, fremanezumab, galcanezumab (Aimovig®, AJOVY®, Emgality®) for the treatment of patients with episodic and chronic migraine

de boer J, Wijma S
Record ID 32018002683
Project Status: Completed
Year Published: 2021
English language abstract: An English language summary is available
Publication Type: Other
Country: The Netherlands
MeSH Terms
  • Migraine Disorders
  • Calcitonin Gene-Related Peptide Receptor Antagonists
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • CGRP inhibitor erenumab
Organisation Name: The National Health Care Institute (ZIN, Zorginstituut Nederland)
Contact Address: Postbus 320, NL-1110 AH Diemen The Netherlands
Contact Name: Timon Sibma
Contact Email: TSibma@zinl.nl
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.